Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion

Vascular endothelial growth factor (VEGF) undergoes alternative splicing to produce both proangiogenic and antiangiogenic isoforms. Preferential splicing of proangiogenic VEGF is determined by serine-arginine protein kinase 1 (SRPK1), which is upregulated in a number of cancers.

In the present study, we aimed to investigate SRPK1 expression in prostate cancer (PCa) and its association with cancer progression. SRPK1 expression was assessed using immunohistochemistry of PCa tissue extracted from radical prostatectomy specimens of 110 patients. SRPK1 expression was significantly higher in tumour compared with benign tissue (p

Journal of clinical pathology. 2015 Oct 23 [Epub ahead of print]

Nicholas Bullock, Jonathan Potts, Andrew J Simpkin, Anthony Koupparis, Steve J Harper, Jon Oxley, Sebastian Oltean

School of Physiology and Pharmacology, University of Bristol, Bristol, UK. , Department of Urology, Southmead Hospital, Bristol, UK. , School of Social and Community Medicine, University of Bristol, Bristol, UK. , Department of Urology, Southmead Hospital, Bristol, UK. , School of Physiology and Pharmacology, University of Bristol, Bristol, UK. , Department of Cellular Pathology, Southmead Hospital, Bristol, UK. , School of Physiology and Pharmacology, University of Bristol, Bristol, UK.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe